ABL and Odimma Therapeutics Partner to Advance Personalized Cancer Immunotherapy

Strengthening Manufacturing Capabilities for the ODI-2001 Platform.

Odimma Therapeutics and ABL Europe, a leading contract development and manufacturing organization (CDMO) specializing in viral vector production, entered into a strategic development agreement to support the advancement of ODI-2001, Odimma’s personalized cancer immunotherapy platform.

Under the collaboration, ABL will manufacture the viral component of ODI-2001, a key element designed to both stimulate the immune system and deliver patient-specific neoantigen DNA. The production of GMP-grade material will support future clinical development and pave the way toward early commercialization.

The partnership represents an important milestone in Odimma’s industrial strategy, combining innovative personalized immunotherapy with world-class biomanufacturing expertise.

Commenting on the agreement, Dr. Jean-Marc Limacher, Chairman of Odimma Therapeutics, emphasized the importance of ABL’s expertise in producing the viral component required for the company’s first clinical program. Patrick Mahieux, Managing Director of ABL Europe, highlighted the shared ambition to develop innovative solutions for patients facing difficult-to-treat cancers.

By strengthening its manufacturing ecosystem through strategic partnerships, Odimma continues to build the foundations for the next generation of precision oncology therapies.